龍津藥業(002750.SZ)業績快報：2019年淨虧損2452.88萬元
格隆匯4月13日丨龍津藥業(002750.SZ)披露2019年度業績快報，實現營業總收入2.75億元，同比下降18.06%；利潤總額-2276.87萬元；歸屬於上市公司股東的淨虧損2452.88萬元，上年同期盈利1387.01萬元；基本每股虧損0.0612元。
公司2019年度經營業績變動(虧損)的主要原因如下：
(1)公司及全資子公司南澗龍津生物科技有限公司、南澗龍津農業科技有限公司收到雲南三七科技有限公司的《民事起訴狀》：雲南三七科技有限公司以股權轉讓糾紛為由起訴公司，主張與公司於2018年1月2日簽訂的《關於雲南三七科技燈盞花葯業有限公司100%股權之產權交易補充合同》(“補充合同”)無效。公司積極準備應訴資料，根據謹慎性原則，將資產評估基準日至資產交割日即合併日(即2016年9月30日至2019年7月31日)的過渡期損益從“其他應收款-三七科技”調整至商譽。根據合併日審計報告(中審眾環會計師事務所云南亞太分所出具的眾環雲審字【2019】)1853號及眾環雲審字【2019】1852號)，南澗龍津生物科技有限公司過渡期損益為-1175.61萬元，南澗龍津農業科技有限公司過渡期損益為-473.68萬元。調整前合併日南澗龍津生物科技有限公司商譽為403.07萬元，南澗龍津農業科技有限公司商譽為0萬元。調整後合併日南澗龍津生物科技有限公司商譽為1,876.00萬元，南澗龍津農業科技有限公司商譽為480.45萬元。公司委託評估機構對標的公司截止2019年12月31日的資產組(含商譽)可收回金額進行評估，根據評估機構初步評估結果，預計南澗龍津生物科技有限公司商譽減值1,876.00萬元，資產組減值438.85萬元。預計南澗龍津農業科技有限公司商譽減值480.45萬元。
(2)根據公司與三七科技簽訂的《關於燈盞花葯業100%股權產權交易補充合同》規定：“股權交割日標的公司的全部庫存燈盞花素抵付三七科技的借款，標的公司、甲方、乙方三方清點並書面確定數量，三方約定抵付價格按每千克陸仟叁佰元計算。庫存燈盞花素抵付後超出部分由三七科技按6,300元/千克全部收購”。如果補充合同無效，截止2019年12月31日，庫存商品可變現值會大幅下降，公司將計提存貨跌價準備622.80萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
